Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)
Pfizer heads into the final full trading week before the holidays with a familiar mix of catalysts: pipeline updates that support its post‑COVID growth narrative, dealmaking in the red‑hot obesity space, and renewed regulatory headlines around COVID‑19 vaccines. Add in a freshly declared quarterly dividend and an upcoming 2026 guidance call, and Pfizer stock is setting up for another headline-driven stretch.
